Abu Dhabi: CPhI Middle East & Africa 2019, the global pharmaceutical showcase held in Abu Dhabi, has concluded after welcoming 234 exhibiting companies and over 3,100 visitors, from 98 countries.

His Excellency Sheikh Nahyan bin Mubarak al Nahyan, Minister of Tolerance, opened the event on 16 September, amid the projected US$41 billion the pharmaceutical industry in the MENA region is expected to top by 2022.

Cara Turner, Brand Director, CPhI Middle East & Africa, said: “This year has been about building on the success of the inaugural edition last year and reinforcing the importance of the event, which has been designed to support and grow pharmaceutical manufacturing throughout the region.

“Several exhibitors have already re-signed for the 2020 event, and in doing so also expanded their presence through booking larger stand areas. Our aim for next year is to attract even greater numbers of high-level delegates, visitors, exhibitors and speakers,” added Turner.

The three-day event, which was sponsored by the Ministry of Health and Protection (MoHaP), brought together companies covering every step of the pharma supply chain from drug research to finished dosage including pharma ingredients, product manufacturers, supplies and buyers.  

The exhibition space was broken down into five distinct sectors of the industry, including:

  • CPhI: Brings together buyers, manufacturers and suppliers of pharmaceutical ingredients
  • FDF: Meet with manufacturers from every aspect of the finished dosage supply chain
  • ICSE: Connects the pharma community with CRO and CMO companies and technologies
  • P-MEC: Showcases the newest pharmaceutical machinery, equipment and technology providers
  • InnoPack: Hosts the latest innovations in packaging, integrated solutions and drug delivery systems

Research from the show revealed over 75% of all visitors had purchasing power, thereby connecting prominent and pioneering pharma brands such as Switzerland’s Bachem, French headquartered BD, India’s Vasudha Pharma Chem Ltd and the UAE’s Neopharma, with key partners.  

The onsite conference programme opened with a keynote speech from His Excellency Dr Amin Hussain Al Amiri, Assistant Undersecretary of Public Health Policy & Licensing Sector in UAE Ministry of Health & Prevention, MoHaP. Entitled Healthcare and Pharmaceutical Continuum: Highlights Across the Region, where he addressed a number of topics including a focus on Middle East healthcare systems, creating value for patients and society, R&D investments and an overview on creating a smart regulatory environment for the UAE.

Dr Faisal BinDail, Chairman of the National Committee for Pharmaceutical Industries, outlined plans for future-proofing Saudi Arabia’s pharma development as part of the Kingdom’s Vision 2030.

Speaking at the event Dr. BinDail said: “In the context of Saudi Arabia, Pharma manufacturing holds an important position in achieving the Kingdom’s Vision 2030. The regulatory body, local industry players, global companies have realised the importance of this initiative and are working towards strengthening of localised Pharmaceutical manufacturing.

Focusing on Sub-Saharan African (SSA), Martin Tronquit, Founder and Managing Partner of Infomineo, highlighted the rate of growth of pharma spending in the region and the opportunities for pharma companies to produce products locally. The growth of the market in SSA directly correlated with a 21% increase in visitors to the show when compared to the 2018 edition.

With a series of events held in Europe, North America, Korea, China, India, Japan and Southeast Asia, globally CPhI brings together more than 100,000 pharmaceutical professionals every year.

-Ends-

About CPhI

CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. CPhI hosts events in Europe, North America, Korea, China, India, Japan, Southeast Asia and the Middle East, and co-locates with ICSE for contract services, P-MEC for machinery, equipment & technology, FDF for finished dosage formulations, InnoPack for pharmaceutical packaging and BioPh for biopharma. CPhI provides an online buyer & supplier directory at CPhI-Online.com . 

For more information visit: www.cphi.com 

About Informa Markets

 Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world’s leading exhibitions organiser, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit www.informamarkets.com. 

Media contact
JAMES LAKIE
General Manager
Tel: +971 4 365 2711 | Mobile: +971 50 153 6544
E-mail: james.lakie@shamalcomms.com
Office 106, Arjaan Office Tower, Dubai Media City
PO Box 502701 | Dubai, United Arab Emirates
Website: www.shamalcomms.com 

© Press Release 2019

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.